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2 
Abstract 17 
Fused deposition modeling (FDM) is a 3D printing technique based on the deposition of successive 18 
layers of thermoplastic materials following their softening/melting. Such a technique holds huge 19 
potential for the manufacturing of pharmaceutical products and is currently under extensive 20 
investigation. Challenges in this field are mainly related to the paucity of adequate filaments 21 
composed of pharmaceutical grade materials, which are needed for feeding the FDM equipment. 22 
Accordingly, a number of polymers of common use in pharmaceutical formulation were evaluated 23 
as starting materials for fabrication via hot melt extrusion of filaments suitable for FDM processes. 24 
By using a twin-screw extruder, filaments based on insoluble (ethylcellulose, Eudragit
®
 RL), 25 
promptly soluble (polyethylene oxide, Kollicoat
® 
IR), enteric soluble (Eudragit
®
 L, hydroxypropyl 26 
methylcellulose acetate succinate) and swellable/erodible (hydrophilic cellulose derivatives, 27 
polyvinyl alcohol, Soluplus
®
) polymers were successfully produced, and the possibility of 28 
employing them for printing 600 µm thick disks was demonstrated. The behavior of disks as 29 
barriers when in contact with aqueous fluids was shown consistent with the functional application 30 
of the relevant polymeric components. The produced filaments were thus considered potentially 31 
suitable for printing capsules and coating layers for immediate or modified release, and, when 32 
loaded with active ingredients, any type of dosage forms. 33 
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1. Introduction 42 
Some major challenges that still have to be faced in the field of drug delivery (e.g. drug targeting, 43 
administration of proteins, personalized therapy) and pharmaceutical production (e.g. continuous 44 
manufacturing, optimization) relate to the development and proper application of new 45 
manufacturing techniques, such as hot-processing including hot melt extrusion (HME), injection 46 
molding (IM) and 3D printing (3DP) by fused deposition modeling (FDM) (Maroni et al., 2012; 47 
Park, 2015; Mascia et al., 2013, Melocchi et al, 2015a; Norman et al., 2016; Shah et al., 2013; Zema 48 
et al., 2012). As far as 3DP is concerned, it has gained huge interest in recent years after finding 49 
widespread application in many industrial domains (e.g. automotive, aerospace, fashion and 50 
defense), where it is also exploited as a rapid prototyping tool. In this respect, it allows a 51 
representation of an item to be created before its final release or commercialization, thus reducing 52 
time and costs of the development. Moreover, 3DP turned out to be promising in the biomedical 53 
field for producing personalized prostheses on the basis of each patient's characteristics and needs, 54 
as identified by imaging techniques (e.g. x-ray computed tomography, nuclear magnetic resonance) 55 
(Rengier et al., 2010). 3DP includes a variety of techniques (e.g. stereolithography, selective laser 56 
sintering, fused deposition modeling). They all enable the fabrication of objects starting from digital 57 
models through the addition of successive layers (i.e. additive manufacturing), while differing in the 58 
starting materials and additive processes employed (Gibson et al. 2010; Pham and Gault, 1998). 59 
3DP based on both powder solidification, first developed at Massachusetts Institute of Technology, 60 
and extrusion, was recently proposed for the development of drug products (Norman et al., 2016; 61 
Prasad and Smyth, 2015; Yu et al., 2008). Indeed, in 2015 the first 3D printed drug product 62 
(Spritam
®
) was approved by US Food and Drug Administration agency (FDA) 63 
(http://www.drugs.com/newdrugs/fda-approves-spritam-levetiracetam-first-3d-printed-product-64 
4240.html; http://www.spritam.com). It is a tablet that can be loaded with differing doses (up to 65 
1000 mg) of levetiracetam, manufactured through the Aprecia's ZipDose
®
 technology. This exploits 66 
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3DP by powder solidification to produce a porous orodispersible formulation that rapidly 67 
disintegrates in a very low amount of liquid. 68 
FDM is an extrusion-based 3DP technique easily accessible, low-cost, versatile and characterized 69 
by a good potential for fabrication of single-unit dosage forms (Goyanes et al., 2015a; Norman et 70 
al., 2016; Yu et al., 2008). It allows the type, dose, and distribution of the active ingredient as well 71 
as the size, shape, geometry (e.g. hollow, multi-layer, coated) and density of the final product to be 72 
varied, thus ideally meeting the needs of personalized medicine (Goyanes et al., 2015b and c; 73 
Melocchi et al., 2015b; Skowyra et al., 2015). FDM consists in the deposition, on a build plate, of 74 
molten/softened materials from a heated printer extrusion head that moves along the x and y axes, 75 
while lowering of the build plate enables the growth of the item bottom-up (Gibson et al., 2010). 76 
Starting materials are generally supplied in the form of filaments, which are produced by HME. The 77 
first commercially available filaments were mainly based on acrylonitrile butadiene styrene (ABS) 78 
and polylactic acid (PLA). Because of the increasing interest in FDM, the fabrication of filaments 79 
has become an important research area. Therefore, not only the use of other materials was explored, 80 
e.g. polyvinyl alcohol (PVA), XT copolyester, polyethylene terephthalate, nylon, thermoplastic 81 
polyurethane, but also different physical/mechanical properties of filaments (e.g. color, resistance, 82 
flexibility) were pursued. In the pharmaceutical field, early attempts were carried out using plastics 83 
(e.g. ethylene vinyl acetate, PLA, PVA) also in the form of filaments available on the market, 84 
introducing the active ingredient by soaking or extrusion (Genina et al., 2016; Goyanes et al., 2014; 85 
Goyanes et al., 2015a, b, c and d; Holländer, et al., 2016; Sandler et al., 2014; Skowyra et al., 2015; 86 
Water et al., 2015). Only very recently, a few drug-containing monolithic units intended for oral 87 
administration were described based on purposely-extruded filaments (Pietrzak at al., 2015). 88 
Moreover, starting from filaments based on hydroxypropyl cellulose (HPC), hollow items in the 89 
form of caps and bodies to be assembled in a capsule shell for pulsatile release were prepared 90 
(Melocchi et al., 2015b). FDM was also demonstrated a suitable prototyping tool for 91 
swellable/erodible capsular delivery platforms prepared by IM (Gazzaniga et al., 2011; Macchi et 92 
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al., 2015; Melocchi et al., 2015b; Zema et al., 2013a). However, few thermoplastic materials were 93 
investigated so far, none of which is commercially available as filaments. Hence, in view of the 94 
variety of polymeric materials used in the manufacturing of dosage forms and DDSs, investigations 95 
in this respect need to be broadened. The availability of libraries of polymeric filaments, which may 96 
differ in terms of physico-technological characteristics and processing conditions while allowing 97 
products with comparable performance to be obtained, could be of great interest, for instance to 98 
circumvent stability issues related to the operating temperatures involved by each material. 99 
Based on these premises, the aim of the present work was to produce filaments suitable for FDM 100 
starting from a variety of pharmaceutical grade polymers having differing physico-chemical 101 
characteristics. Particularly, insoluble, promptly soluble, enteric soluble and swellable/erodible 102 
polymers were considered. Such filaments would be intended for fabrication of capsule shells and 103 
coatings for either immediate or modified release. In addition, they could be loaded with active 104 
ingredients and then employed for the manufacturing of printed monolithic drug products (e.g. 105 
pellets, tablets, matrices). 106 
 107 
2. Materials and Methods 108 
2.1 Materials 109 
Polylactic acid, PLA filament (L-PLA natural, ø 1.75 mm; MakerBot
® Industries, LLC, US-NY); 110 
ethyl cellulose, EC (Ethocel™ Std. 100 premium, Dow, US-MY); hydroxypropyl cellulose, HPC 111 
(Klucel
®
 LF, Ashland, US-NJ); hydroxypropyl methyl cellulose, HPMC (Affinisol
™
 15cP, Dow, US-112 
CA); hydroxypropyl methyl cellulose acetate succinate, HPMCAS (AQUOT-LG
®
; Shin-Etsu, J); 113 
methacrylic acid copolymer Eudragit
®
 L 100-55, EDR L, and Eudragit
®
 RL PO, EDR RL (Evonik, D); 114 
polyethylene oxide, PEO (Sentry Polyox ™ WSR N10 LEO NF, Colorcon, UK); polyvinyl alcohol, 115 
PVA (Gohsenol
® 
EG 05P, Nippon Goshei, J); polyvinyl alcohol-polyethylene glycol graft copolymer, 116 
KIR (Kollicoat
®
 IR, BASF, D); polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-117 
polymer, SLP (Soluplus
®
, BASF, D); glycerol, GLY (Pharmagel, I); polyethylene glycols, PEG 400 and 118 
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PEG 8000 (Clariant Masterbatches, I); triethyl citrate, TEC (Sigma Aldrich, D); acetaminophen, AAP 119 
(Rhodia, I); furosemide, FUR (Metapharmaceutical, E). 120 
 121 
2.2 Methods 122 
PLA filament was used as received. All materials, except for PEGs, GLY, TEC, AAP and FUR, were 123 
kept in an oven at 40 °C for 24 h prior to use. Plasticized polymeric formulations were prepared by 124 
mixing polymers with the selected plasticizer in a mortar. The amount of plasticizer was expressed as % 125 
by weight on the dry polymer. FUR was added to the KIR-based formulation by mixing in a mortar and 126 
its amount was expressed as % by weight on the final mixture (i.e. 30%). 127 
 128 
2.1.1 Preparation of filaments 129 
Filaments were prepared by HME using a twin-screw extruder (Haake™ MiniLab II, Thermo Scientific, 130 
US-WI) equipped with counter-rotating screws and a custom-made aluminum rod-shaped die (ø = 1.80 131 
mm); process conditions are reported in the Results section. Extruded rods were manually pulled and 132 
forced to pass through a caliber connected with the extruder and set at 1.80 mm. After production, 133 
filament diameter was verified every 5 cm in length and portions that had not diameter in the acceptable 134 
range of 1.75 ± 0.05 mm were discarded. 135 
 136 
2.1.2 Printing of disks 137 
FDM was performed by an adapted MakerBot Replicator 2 equipped with a 0.4 mm tip (MakerBot
®
 138 
Industries, US-NY; infill = 100%, layer height = 0.30 mm), using a computer-aided design (CAD) file 139 
purposely developed. In particular, a disk (ø = 30 mm and thickness = 600 µm) was designed using 140 
Autodesk
®
 Autocad
®
 2016 software version 14.0 (Autodesk, Inc., US-CA), saved in STL format and 141 
imported to the 3D printer software (MakerWare Version 2.2.2.89, MakerBot
®
 Industries, US-NY). 142 
Either the supplied PLA filament or portions of at least 25 cm of the in-house prepared filaments were 143 
employed.  144 
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The printing temperature was adapted to the thermal and mechanical behavior of each material. When 145 
changing the filament before a new printing process, the printer was cleaned and leveling of the build 146 
plate was performed following assembly of the heating chamber. Cleaning procedure: the temperature 147 
of the heating chamber was set at 250 °C for 3 min; then it was dismounted and the material remaining 148 
in the inner barrel was removed by means of a brass brush. In particular, the nozzle was unscrewed and 149 
any residue inside was manually removed; then it was immersed for at least 3 h in a suitable solvent 150 
depending on the solubility characteristics of the last printed material (e.g. water for KIR and PEO, 151 
acetone for PLA). 152 
 153 
2.1.4 Characterization of disks 154 
Disks were stored between plates before being characterized in terms of weight (analytical balance 155 
BP211, Sartorius, D; n = 6) and thickness (MiniTest FH7200 equipped with FH4 probe, ø sphere = 156 
1.5 mm, ElektroPhysik, D; n = 6), in order to avoid warpage phenomena. Digital photographs of 157 
samples were acquired (Dino Lite Digital Microscope coupled with Dino Capture software, Dino-158 
Lite, VWR International, I). 159 
Thickness was measured in 6 points for each of 3 concentric circumferences (Figure 1). Radius was 160 
of 4mm, 7.5 mm and 13 mm for the inner, intermediate and outer circumference, respectively. 161 
Values were reported as mean and the coefficient of variation (CV) was calculated. 162 
Mass loss test was carried out by a six-position disintegration apparatus (900 mL of distilled water 163 
for KIR, HPC, HPMC, PVA, SLP and EDR RL disks; 2 h in HCl 0.1 N and then pH 6.8 phosphate 164 
buffer, according to Dissolution test for delayed-release dosage forms, Method B, USP 38, for EDR 165 
L and HPMCAS disks; 37 ± 0.5 °C; 31 cycles/min). Before testing, disks were die-cut into smaller 166 
ones (ø = 11 mm) and each of them was checked for weight (initial weight, wi) and inserted into a 167 
single basket-rack assembly. At pre-determined time points, samples (n = 3) were withdrawn, gently 168 
blotted and weighed (wet weigh, ww). Final dry weights (wd) were then determined after oven-169 
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drying (40 °C) to constant weight. The water uptake percentage (% WU) and residual dry mass 170 
percentage (% RDM) were calculated according to the following equations: 171 
 172 
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 176 
Disks were also tested for barrier performance (n = 3). For this purpose, they were mounted to close 177 
manually-assembled cells (area exposed to the medium = 177 mm
2
) (Figure 2) (Zema et al., 2013b). 178 
When testing polymeric disks the donor reservoir compartment was filled with 100 mg of AAP powder 179 
as a tracer (Giordano et al., 2005). The test was performed in a USP 38 dissolution apparatus 2 180 
(Dissolution System 2100B, Distek, US-MA; 900 mL of medium, 100 rpm, 37 ± 0.5 °C). Fluids were 181 
the same as for the mass loss test. Fluid samples were withdrawn at fixed time points and drug was 182 
assayed by spectrophotometer (Lambda25, Perkin Elmer, US-MA; 254 nm). The time to 10% recovery 183 
from the acceptor fluid (t10%) was calculated by linear interpolation of the experimental data 184 
immediately before and after this release %. In the case of enteric-soluble polymers t10% was calculated 185 
after the pH change. 186 
t10% data relevant to swellable/erodible polymer barriers were used to calculate the time equivalent 187 
thickness parameter (TETP) according to the following equation (Sangalli et al., 2004): 188 
        
               
    
 
 189 
where disk thickness is the mean of values measured along the inner and central circumferences (n = 190 
12), in order to consider the surface exposed to the medium only. This parameter expresses the thickness 191 
of the barrier (µm) needed to attain a unit of lag time (min). 192 
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Disks containing FUR and double-disk items were mounted to close the above-mentioned cells, wherein 193 
the donor reservoir compartment was left empty. The test was performed in a USP 38 dissolution 194 
apparatus 2 (Dissolution System 2100B, Distek, US-MA; 1000 mL of medium, 100 rpm, 37 ± 0.5 °C), 195 
under sink conditions. The FUR-containing disk was tested in pH 6.8 phosphate buffer, while the fluids 196 
used to test double-disk items were in those indicated in the Dissolution test for delayed-release dosage 197 
forms, Method B, USP 38. Fluid samples were withdrawn at fixed time points and drug was assayed by 198 
spectrophotometer (Lambda25, Perkin Elmer, US-MA; 274 nm). 199 
 200 
3. Results and Discussion 201 
3.1 Extrusion of filaments and printing of disks 202 
A variety of pharmaceutical grade polymers with different functional applications and a potential 203 
for hot-processing was selected for the manufacturing of filaments by HME. In particular, the use of 204 
a number of promptly soluble (i.e. KIR, PEO), enteric soluble (i.e. HPMCAS, EDR L), 205 
swellable/erodible (i.e. HPC, HPMC, PVA, SLP) and insoluble (i.e. EC, EDR RL) selected 206 
polymers was explored. 207 
The formulation and processing conditions that would allow filaments suitable for feeding a 208 
commercially-available FDM equipment were investigated. A desktop, user-friendly printer, 209 
MakerBot Replicator 2, designed to work with PLA filaments and equipped with a standard 0.4 mm 210 
tip, was employed for 3DP processes. Disk-shaped items of 600 µm in thickness were identified as 211 
viable specimens for the screening of materials. Indeed, though requiring a simple CAD file to be 212 
designed, they could both highlight challenges in filament deposition on account of the limited 213 
thickness/diameter ratio, and provide preliminary information on the achievable performance. 214 
Notably, the possibility of producing thin items having narrow thickness tolerance ranges is of 215 
utmost importance in the pharmaceutical field, especially for the manufacturing of coated dosage 216 
forms or capsular devices. 217 
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In order to explore the feasibility of items having such features, initial trials were performed using 218 
the supplied Makerbot PLA filament and standard printing conditions in compliance with the 219 
technical specifications of the equipment. Based on the CAD file developed, the disks were 220 
automatically fabricated through the addition of two successive layers, the latter being deposited 221 
onto the former perpendicularly on the horizontal plane as envisaged by the 3D printer software. 222 
Prior to each printing step, the build plate needs to be manually levelled, by setting its distance from 223 
the nozzle. Because this operation appeared potentially critical to the vertical growth of the object, 224 
its impact on consistency of the disk thickness was evaluated. Accordingly, 3 leveling replicates by 225 
2 different operators were undertaken. After each of them, a batch of 6 disks was produced. The 226 
disks were characterized in terms of weight and thickness, the latter being measured along 3 227 
concentric circumferences (Table 1). For each leveling replicate, the mean disk weight (n = 6) and 228 
the mean disk thickness from the measurements either along each circumference (n = 6) or all the 3 229 
circumferences (n = 18) were calculated, in order to gain information on intra-operation variability. 230 
In addition, mean weight and thickness values were calculated considering all samples from 231 
different batches (n = 36) in order to also take inter-operation variability into account. 232 
Good results in terms of continuous flow of the material from the nozzle during the printing process 233 
were indicated by the low weight variability (CV < 2). However, thickness data poorly complied 234 
with the value defined in the CAD file (i.e. 600 µm) and showed reproducibility issues. In 235 
particular, intra-operation differences (i.e. among disks printed following the same leveling) up to 236 
about 200 µm and inter-operation differences (i.e. among disks printed following 2 different 237 
levelings) up to about 400 µm were observed. Because disks are composed of 2 layers only, 238 
leveling, which determines the thickness of the former layer by establishing the distance between 239 
the nozzle and the build plate, ultimately affects the final thickness. Moreover, these results 240 
highlighted inherent resolution limits of the printer, used under standard operating conditions (e.g. 241 
PLA filament and 0.4 mm tip), which would have to be taken into account when the quality 242 
standards of pharmaceutical products need to be fulfilled. 243 
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With regard to the extrusion of filaments from the selected pharmaceutical grade polymers, the type 244 
and amount of plasticizers were adjusted, based on the torque values recorded, to enable continuous 245 
extrusion throughout the barrel of the employed equipment that has limited length (12 cm). This 246 
would indeed result in relatively short-lasting exposure of the material to the temperature and shear 247 
stress conditions that cause its softening/melting. Previous 3DP trials pointed out the need for 248 
filaments with a minimum length of 25 cm, circular cross section and proper diameter as well as 249 
diameter tolerances (1.75 ± 0.05 mm) (Melocchi et al., 2015b). For the purpose of producing 250 
suitable filaments, the twin-screw extruder used was equipped with a custom-made aluminum die 251 
having a conical section at the entry side and a cylindrical section at the exit. The extruded 252 
filaments were then pulled manually through a gauge of 1.80 mm to maintain the desired diameter. 253 
The size of filaments, checked every 5 cm, turned out slightly lower than the PLA one (mean = 1.71 254 
mm, CV 2.30 vs 1.79 mm, CV 1.10). Not only the diameter but also the mechanical properties of 255 
the filament were critical to 3DP processability. Problems of rupture or wrapping around gears were 256 
initially encountered. In order to overcome these issues, the feeding mechanism of the printer was 257 
modified by replacing the standard spring with one of lower stiffness, thus reducing the 258 
compression force applied and possibly broadening the range of formulations that could be used. 259 
When feeding failure still occurred, small increases or decreases in the amount of plasticizer (1%), 260 
depending on whether rupturing or wrapping problems had to be faced, respectively, were 261 
systematically attempted. This trial and error approach was continued until formulations suitable for 262 
both extrusion of filaments and feeding of the printer were attained. 263 
The formulation and the extrusion as well as FDM processing conditions relevant to each polymer 264 
investigated, along with photographs of the extruded filaments and printed disks, are reported in 265 
Table 2. 266 
The temperature needed for printing generally turned out to be higher than for extrusion of 267 
filaments. This may be due to the short residence time of the material in the heating chamber of the 268 
3D printer and, also, to the limited contribution of the shear stress developed by the loading gear, if 269 
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compared with the counter-rotating tween-screws of the extruder. Problems of nozzle clogging 270 
following increase in the melt viscosity, caused by decrease in the FDM processing temperature, 271 
were already described (Pietrzak at al., 2015). Moreover, because an unheated build plate was used, 272 
as involved by the standard configuration of Makerbot Replicator 2, the temperature of the material 273 
flowing out from the heating chamber also needed to compensate for the sudden cooling occurring 274 
on deposition, which could hinder proper adherence of the layers to each other and to the surface of 275 
the plate. Removal of disks from the build plate without damaging was in all cases possible because 276 
of sufficient cohesion between the overlapping layers. The extent of plasticization was found 277 
critical in this respect. 278 
The printing process took approximately 2 min per disk. Entire printed disks were obtained, 279 
wherein the 90° deposition pattern was evident (Table 2). When trying to improve the printing 280 
resolution, disks with the required physico-technological characteristics were not always obtained. 281 
High-resolution setting necessarily involves decreased rate of deposition and reduced layer 282 
thickness, and this may have worsened issues related to sudden cooling of the melt. 283 
Weight and thickness data of disks are reported in Table 3. 284 
The variability of both weight and thickness turned out increased with respect to disks printed from 285 
the Makerbot supplied PLA filament though using the same CAD file. Moreover, the average 286 
thickness of the disks based on pharmaceutical grade polymers was generally lower than the 287 
nominal value, ranging from less than 500 µm to approximately 600 µm. Such results were partly 288 
expected due to the inherent characteristics of each material, such as the rheological behavior when 289 
melt and the possible tendency to volumetric changes after hot-processing (Zema et al., 2013a), and 290 
could also be ascribed to problems of continuous loading of the equipment. These would depend on 291 
the variability in diameter of the filaments produced in-house and their mechanical properties. 292 
Besides, such filaments were thinner than the supplied PLA one, ranging on average from 1.70 mm 293 
to 1.74 mm in diameter, which would impact on the thickness of the printed layers, especially when 294 
considering that the 3D printer is set for a filament of 1.77 mm in diameter. It should be noted that, 295 
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the possibility of modifying the CAD file to account for the volumetric changes of the material 296 
following printing was already exploited with HPC (Melocchi et al., 2015b). 297 
 298 
3.2 Evaluation of the barrier performance of printed disks 299 
Disks were used as a simple model to evaluate the performance of printed barriers when in contact 300 
with aqueous fluids, i.e. coatings and capsule shells. For this purpose, the disks were positioned to 301 
close purposely-developed cells with a donor compartment that was filled with a drug tracer (Zema 302 
et al., 2013b). The assembled cells were immersed in an acceptor medium and tests were carried out 303 
in a dissolution apparatus 2. By assaying the drug recovered in the medium over time, cumulative 304 
curves were obtained. 305 
The behavior of disks based on promptly soluble polymers (i.e. KIR and PEO) was first explored 306 
(Figure 3). With either polymeric barriers the whole amount of drug was found in the acceptor 307 
medium after 15 min of testing. A further improvement in terms of dissolution rate could be 308 
achieved by reducing the disk thickness. The dissolution of disks was rapidly completed after their 309 
rupturing occurring within 5 and 10 min in the case of KIR and PEO, respectively. Also, mass loss 310 
tests, carried out under different hydrodynamic conditions, showed that the printed samples based 311 
on both materials entirely dissolved in 3 min. According to these results, KIR and PEO could be 312 
employed as main components of coatings or capsules for immediate-release fabricated by FDM. 313 
These printed capsules could represent an alternative to the gelatin and HPMC ones currently 314 
available. 315 
Disks based on the swellable/erodible polymers under investigation displayed the expected delay 316 
prior to recovery of the drug tracer in the acceptor medium. Indeed, during the test they showed the 317 
typical swelling and erosion/dissolution phenomena upon hydration, until break-up of the barrier. 318 
After this lag phase, a fast increase in the amount of drug recovered in the medium was observed. 319 
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Such a pattern is typical of DDSs for pulsatile release. By way of example, individual profiles 320 
relevant to HPMC-based disks are shown in Figure 4. 321 
The curves presented are characterized by different lag times (t10% ≈ 65, 75 and 85 min). Such 322 
differences would at least partly be due to the diverse thickness values of each sample, i.e. 482 µm 323 
(CV 7.6); 582 µm (CV 6.1), 603 µm (CV 3.2). The influence of the barrier thickness and of the 324 
physico-chemical properties of the selected polymers on lag time is well-known and has largely 325 
been demonstrated in the case of swellable/erodible reservoir systems prepared by IM, film-coating, 326 
powder-layering and compression coating (Del Curto et al., 2014; Gazzaniga et al., 2011; Maroni et 327 
al., 2013a and b; Maroni et al., 2016; Sangalli et al., 2009; Zema et al., 2013a). In order to compare 328 
printed disks based on the various polymers investigated, a previously introduced index was 329 
employed, the time equivalent thickness parameter (TETP), which expresses the thickness of a 330 
polymeric layer needed to attain a lag time of 1 min (Table 4) (Sangalli et al., 2004). As expected, 331 
TETP values pointed out a different efficiency of these polymers. The behavior of printed disks 332 
based on SLP, purposely developed for the achievement of solid dispersions of poorly-soluble 333 
drugs by HME, was comparable with that of barriers based on swellable polymers of established 334 
use in the manufacturing of DDSs for pulsatile release. 335 
The overall results pointed out the availability of a number of hydrophilic polymers other than HPC 336 
that could be suitable for printing capsule shells and for modulating the onset of drug release 337 
(Melocchi et al., 2015b). 338 
From EC and EDR RL, poorly-permeable insoluble disks were obtained. Indeed, the amount of 339 
drug recovered in the acceptor fluid increased very slowly, particularly when dealing with the EC 340 
barrier (Figure 5). In this respect, although hot-processing techniques are known to lead to high-341 
density structures, FDM may grant the possibility of achieving different porosity characteristics 342 
based on printing parameters, such as primarily on how close the layers are deposited (Loreti et al., 343 
2014; Melocchi et al., 2015a). The addition of channeling agents into the filament formulation may 344 
also enhance the barrier permeability. The low rate of drug permeation could also be attributed to 345 
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the relatively high thickness of the printed disks as compared with films commonly applied to solid 346 
dosage forms in order to prolong the drug release over time. Fabrication of thinner barriers, which 347 
would most likely be intended for using as coatings rather than capsule shells, could represent a 348 
further strategy to achieve release rates consistent with the oral administration route. 349 
Finally, the barriers based on enteric soluble polymers, i.e. HPMCAS and EDR L, were evaluated 350 
by using HCl 0.1 N and then phosphate buffer pH 6.8 as the acceptor fluids. The disks showed the 351 
expected resistance when in contact with the acidic medium. When switching to phosphate buffer, a 352 
lag time elapsed before dissolution and consequent rupture of the barriers. Such lag time was of 353 
40.42 min (CV 7.32) and 45.95 min (CV 12.23) with HPMCAS and EDR L, respectively. From 354 
HPMCAS-based disks and capsular devices manufactured by IM, a lag time before dissolution of 355 
the enteric soluble polymer was analogously observed (Zema et al., 2013b). In that case, the time 356 
taken for this process was shortened by adding channeling agents and/or reducing the thickness of 357 
molded barriers, which could also be exploited with 3D printed items. 358 
 359 
3.3 Printing and evaluation of double-disk items 360 
In order to preliminarily evaluate the feasibility of FDM in the fabrication of coated dosage forms, a 361 
double-disk item was obtained by successively printing two overlaid disks of different composition, 362 
with no need for a newly designed CAD file. The filament for the former disk was extruded starting 363 
from the KIR-based formulation containing furosemide (30% by weight), a poorly-soluble active 364 
ingredient having high-melting point. The hot-processability of this model drug was already 365 
demonstrated when mixed with the same polymer (Melocchi et al., 2015a). The latter disk was 366 
based on HPMCAS. 367 
The impact of the drug on the process parameters and quality of the product was negligible not only 368 
as regards HME, as expected on the basis of previous experience, but also in the case of FDM. 369 
After printing of the former disk, the remainder of the material was completely removed from the 370 
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heating chamber of the 3D printer by a purge operation before feeding the latter filament, which 371 
required to be processed at a higher temperature. Re-leveling was then performed with respect to 372 
the printed furosemide-containing disk. At the end of the process, the two parts of the double-disk 373 
item tightly adhered to each other, and the overall thickness was of 1052 µm (CV 12.7). For 374 
comparison purposes, single-disks containing furosemide were also printed. 375 
Double-disk items were positioned into the cells for evaluation of performance, so that the enteric-376 
soluble side was in contact with the medium and the drug-containing one was oriented towards the 377 
empty donor compartment. During the acidic stage of the test no drug was recovered in the acceptor 378 
medium, thus indicating that gastroresistance was effective (Figure 6). In the pH 6.8 fluid, the drug 379 
was released after a lag phase (t10% = 49.06 min, CV 6.26) that turned out comparable in duration 380 
with that previously assessed when testing the HPMCAS disks as such. Moreover, the release 381 
pattern after the lag phase was analogous to that obtained from single furosemide-containing disks. 382 
These are the typically results that are observed from enteric-coated dosage forms. 383 
 384 
4. Conclusions 385 
Filaments based on a variety of pharmaceutical grade polymers, i.e. Kollicoat
®
 IR, PEO, HPC, 386 
HPMC, PVA, Soluplus
®
, EC, Eudragit
®
 RL, Eudragit
®
 L and HPMCAS, were successfully 387 
produced, which turned out suitable for 3D printing by FDM. From filaments based on all these 388 
materials, disk-shaped specimens having thickness on the order of hundreds of microns were 389 
obtained. The printed disks were proved advantageous to investigate both the processability of the 390 
polymers and their behavior in contact with aqueous fluids after processing. When used as barriers, 391 
such disks performed as promptly-soluble, swellable/erodible, slowly-permeable insoluble and 392 
gastroresistant layers, consistent with the nature of their polymeric components and main 393 
applications in pharmaceutical formulation. Moreover, multiple overlaid disks were shown feasible. 394 
Overall, the potential of the investigated materials when processed by FDM was demonstrated for 395 
the manufacturing of immediate-release capsules, delivery platforms based on capsular devices and 396 
17 
cosmetic or functional coating layers. In addition, a variety of further products, such as tablets and 397 
matrices, could be obtained by incorporating active ingredients into the filaments. 398 
As occurred in the past when transferring other industrial technologies to the pharmaceutical field 399 
(e.g. pelletization, HME, IM), a full exploitation of FDM and relevant broad application in this area 400 
actually require the development of suitable equipment and processes, which would enable the 401 
manufacturing of products complying with the strict quality standards involved. 402 
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5. References 404 
Del Curto M. D., Palugan L., Foppoli A., Zema L., Gazzaniga A., Maroni A.,  Erodible time-405 
dependent colon delivery systems with improved efficiency in delaying the onset of drug release, J. 406 
Pharm. Sci., 103: 3585-3593 (2014). 407 
Gazzaniga A., Cerea M., Cozzi A., Foppoli A., Maroni A., Zema L., A novel injection-molded 408 
capsular device for oral pulsatile delivery based on swellable/erodible polymers, AAPS 409 
PharmSciTech., 12: 295-303 (2011). 410 
Genina N., Holländer J., Jukarainen H., Mäkilä E., Salonen J., Sandler N., Ethylene vinyl acetate 411 
(EVA) as a new drug carrier for 3D printed medical drug delivery devices, Eur. J. Pharm. Sci., 412 
http://dx.doi.org/10.1016/j.ejps.2015.11.005 (2016). 413 
Gibson I., Rosen D. W., Stucker B., Additive Manufacturing Technologies: rapid prototyping to 414 
direct digital manufacturing, Springer, New York (2010). 415 
Giordano F., Rossi A., Bettini R., Savioli A., Gazzaniga A., Novák Cs., Thermal behavior of 416 
paracetamol polymeric excipients mixtures, J. Therm. Anal. Calorim., 68: 575-590 (2002). 417 
Goyanes A., Buanz A. B. M., Basit A. W., Gaisford S., Fused-filament 3D printing (3DP) for 418 
fabrication of tablets, Int. J. Pharm., 476: 88-92 (2014). 419 
18 
Goyanes A., Robles Martinez P., Buanz A., Basit A. W., Gaisford S., Effect of geometry on drug 420 
release from 3D printed tablets , Int. J. Pharm., 494: 657-663 (2015a). 421 
Goyanes A., Chang H., Sedough D., Hatton G. B., Wang J., Buanz A., Gaisford S., Basit A. W., 422 
Fabrication of controlled-release budesonide tablets via desktop (FDM) 3D printing, Int. J. Pharm., 423 
496: 414-420 (2015b). 424 
Goyanes A., Wang J., Buanz A., Martínez-Pacheco R., Telford R., Gaisford S., Basit A. W., 3D 425 
Printing of medicines: engineering novel oral devices with unique design and drug release 426 
characteristics, Mol. Pharm., 12: 4077-4084 (2015c). 427 
Goyanes A., Buanz A. B. M., Hatton G. B., Gaisford S., Basit A. W., 3D printing of modified-428 
release aminosalicylate (4-ASA and 5-ASA) tablets, Eur. J. Pharm. Biopharm., 89: 157-162 429 
(2015d). 430 
Holländer J., Genina N., Jukarainen H., Khajeheian M., Rosling A., Mäkilä E., Sandler N.,Three-431 
dimensional printed PCL-based implantable prototypes of medical devices for controlled drug 432 
delivery, J. Pharm. Sci., doi:10.1016/j.xphs.2015.12.012 (2016). 433 
http://www.drugs.com/newdrugs/fda-approves-spritam-levetiracetam-first-3d-printed-product-434 
4240.html (accessed on 04/05/2016). 435 
http://www.spritam.com (accessed on 04/05/2016). 436 
Loreti G., Maroni A., Del Curto M. D., Melocchi A., Gazzaniga A., Zema L., Evaluation of hot 437 
melt extrusion technique in the production of HPC matrices for prolonged release, Eur. J. Pharm. 438 
Sci., 52: 77-85 (2014). 439 
Macchi E., Zema L., Maroni A., Gazzaniga A., Felton L. A., Enteric-coating of pulsatile-release 440 
HPC capsules prepared by injection molding, Eur. J. Pharm. Sci., 70: 1-11 (2015). 441 
19 
Maroni A., Zema L., Del Curto M. D., Foppoli A., Gazzaniga A., Oral colon delivery of insulin 442 
with the aid of functional adjuvants, Adv. Drug Deliv. Rev., 64: 540-556 (2012). 443 
Maroni A., Zema L., Loreti G., Palugan L., Gazzaniga A., Film coatings for oral pulsatile release, 444 
Int. J. Pharm., 457: 362-371 (2013a). 445 
Maroni A., Del Curto M. D., Zema L., Foppoli A., Gazzaniga A., Film coatings for oral colon 446 
delivery, Int. J. Pharm., 457: 372-394 (2013b). 447 
Maroni A., Zema L., Cerea M., Foppoli A., Palugan L., Gazzaniga A., Erodible drug delivery 448 
systems for time-controlled release into the gastrointestinal tract, J. Drug Deliv. Sci. Technol., 32: 449 
229-235 (2016). 450 
Mascia S., Heider P. L., Zhang H., Lakerveld R., Benyahia B., Barton P. I., Braatz R. D., Cooney 451 
C. L., Evans J. M. B., Jamison T. F., Jensen K. F., Myerson A. S., Trout B. L., End-to-end 452 
continuous manufacturing of pharmaceuticals: integrated synthesis, purification, and final dosage 453 
formation, Angew. Chem. Int. Ed. Engl., 52: 12359-12363 (2013). 454 
Melocchi A., Loreti G., Del Curto M. D., Maroni A., Gazzaniga A., Zema L., Evaluation of hot 455 
melt extrusion and injection molding for continuous manufacturing of immediate release tablets, J. 456 
Pharm. Sci., 104: 1971-1980 (2015a). 457 
Melocchi A., Parietti F., Loreti G., Maroni A., Gazzaniga A., Zema L., 3D printing by fused 458 
deposition modeling (FDM) of a swellable/erodible capsular device for oral pulsatile release of 459 
drugs, J. Drug. Deliv. Sci. Technol., 30 Part B: 360-367 (2015b). 460 
Norman J., Madurawe R. D., Moore C. M. V., Khan M. A., Khairuzzaman A., A new chapter in 461 
pharmaceutical manufacturing: 3D-printed drug, Adv. Drug Deliv. Rev., 462 
doi:10.1016/j.addr.2016.03.001 (2016). 463 
Park K., 3D printing of 5-drug polypill, J. Control. Release, 217: 352 (2015). 464 
20 
Pietrzak K., Isreb A., Alhnan M. A., A flexible-dose dispenser for immediate and extended release 465 
3D printed tablets, Eur. J. Pharm. Biopharm., 96: 380-387 (2015). 466 
Pham D. T., Gault R. S., A comparison of rapid prototyping technologies, Int. J. Mach. Tools 467 
Manuf., 38: 1257-1287 (1998). 468 
Prasad L. K., Smyth H., 3D Printing technologies for drug delivery: a review, Drug Dev. Ind. 469 
Pharm., 13: 1-13 (2015). 470 
Rengier F., Mehndiratta A., von Tengg-Kobligk H., Zechmann C. M., Unterhinninghofen R., 471 
Kauczor H. U., Giesel F. L., 3D printing based on imaging data: review of medical applications, Int. 472 
J. Comput. Assist. Radiol. Surg., 5: 335-341 (2010). 473 
Sandler N., Salmela I., Fallarero A., Rosling A., Khajeheian M., Kolakovic R., Genina N., Nyman 474 
J., Vuorela P., Towards fabrication of 3D printed medical devices to prevent biofilm formation, Int. 475 
J. Pharm., 459: 62-64 (2014). 476 
Sangalli M. E., Maroni A., Foppoli A., Zema L., Giordano F., Gazzaniga A., Different HPMC 477 
viscosity grades as coating agents for an oral time and/or site-controlled delivery system: a study on 478 
process parameters and in vitro performances, Eur. J. Pharm. Sci., 22: 469-476 (2004). 479 
Sangalli M. E., Maroni A., Zema L., Cerea M., Gazzaniga A., The Chronotopic™ technology, in: 480 
B.-B.C. Youan (Ed.), Chronopharmaceutics. Science and technology for biological rhythm guided 481 
therapy and prevention of diseases, John Wiley&Sons, Hoboken, New Jersey, pp. 145-163 (2009). 482 
Skowyra J., Pietrzak K., Alhnan M. A., Fabrication of extended-release patient-tailored 483 
prednisolone tablets via fused deposition modelling (FDM) 3D printing, Eur. J. Pharm. Sci., 68: 11-484 
17 (2015). 485 
Shah S., Maddineni S., Lu J., Repka M. A., Melt extrusion with poorly soluble drugs, Int. J. Pharm., 486 
453: 233-52 (2013). 487 
21 
Water J. J., Bohr A., Boetker J., Aho J., Sandler N., Nielsen H. M., Rantanen J., Three-dimensional 488 
printing of drug-eluting implants: preparation of an antimicrobial polylactide feedstock material, J. 489 
Pharm. Sci., 104:1099-1107 (2015). 490 
Yu D. G., Zhu L. M., Branford-White C. J., Yang X. L., Three-dimensional printing in 491 
pharmaceutics: promises and problems, J. Pharm. Sci., 97: 3666-3690 (2008). 492 
Zema L., Loreti G., Melocchi A., Maroni A., Gazzaniga A., Injection molding and its application to 493 
drug delivery, J. Control. Release, 159: 324-331 (2012). 494 
Zema L., Loreti G., Melocchi A., Maroni A., Palugan L., Gazzaniga A., Gastroresistant capsular 495 
device prepared by injection molding, Int. J. Pharm., 440: 264-272 (2013b). 496 
Zema L., Loreti G., Macchi E., Foppoli A., Maroni A., Gazzaniga A., Injection-molded capsular 497 
device for oral pulsatile release: development of a novel mold, J. Pharm. Sci., 102: 489-499 498 
(2013a). 499 
  
Table 1: weight and thickness of PLA disks fabricated after 3 leveling of the build plate by 2 
different operators 
 
 
Leveling 
replicate 
Weight 
mg (CV) 
n = 6 
Thickness 
µm (CV) 
Outer 
circumference 
n = 6 
Intermediate 
circumference 
n = 6 
Inner 
circumference 
n = 6 
All circumferences 
n = 18 
Operator 1 
I 514.6 (1.7) 636 (4.1) 626 (5.1) 622 (5.2) 628 (4.8) 
II 514.4 (0.5) 680 (5.6) 665 (4.6) 673 (6.6) 673 (5.6) 
III 520.9 (0.2) 720 (8.0) 706 (5.6) 724 (8.9) 717 (7.6) 
Operator 2 
I 507.5 (1.3) 643 (6.9) 633 (4.7) 635 (5.6) 637 (5.7) 
II 525.4 (0.2) 737 (5.0) 736 (6.3) 739 (3.6) 738 (4.9) 
III 533.9 (0.2) 844 (8.9) 838 (7.2) 832 (7.2) 832 (7.8) 
All leveling replicates 
n = 36 
519.5 (1.8) 710 (12.0) 701 (11.8) 701 (11.0) 704 (11.7) 
 
Table(s)
 Table 2: formulation, process parameters and photographs relevant to extruded filaments and 
printed disks (entire and magnified detail) based on different pharmaceutical grade polymers 
 
FORMULATION 
HME FDM 
T 
(°C) 
Screw 
speed (rpm) 
Torque 
(N·cm) 
Product  
T 
(°C) 
Product 
 
5 mm 
 
10 mm 
x 10 
magnification 
KIR + 
12% GLY 
160 100 80 
 
180 
  
PEO 65 100 100 
 
160 
  
HPMC + 
5% PEG 400 
160 70 70 
 
200 
  
HPC 165 80 40 
 
180 
  
PVA+ 
5% GLY 
190 70 80 
 
225 
  
SLP +  
10% PEG 400 
120 80 80 
 
200 
  
HPMCAS + 
5% PEG 8000 
180 100 100 
 
200 
   
EDR L + 
20% TEC 
160 80 120 
 
160 
  
EDR RL + 
15% TEC 
120 95 60 
 
160 
  
EC + 
10% TEC  
160 100 100 
 
200 
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 Table 3: weight and thickness data of printed disks based on different pharmaceutical grade 
polymers 
 
FORMULATION 
Weight 
mg (CV) 
Thickness 
µm (CV) 
Outer 
circumference 
n = 6 
Intermediate 
circumference 
n = 6 
Inner 
circumference 
n = 6 
All 
circumferences 
n = 18 
KIR + 12% GLY 477.4 (3.8) 634 (9.2) 601 (5.7) 623 (7.6) 614 (7.5) 
PEO 364.0 (12.8) 571 (10.6) 563 (11.2) 555 (14.0) 563 (11.9) 
HPMC + 5% PEG 400 435.7 (9.2) 605 (12.8) 559 (10.7) 526 (12.7) 563 (11.4) 
HPC 423.3 (2.0) 645 (5.9) 635 (6.2) 634 (5.2) 638 (5.8) 
PVA+ 5% GLY 352.0 (10.3) 528 (8.9) 545 (12.8) 527 (6.5) 533 (9.9) 
SLP + 10% PEG 400 325.0 (13.6) 543 (18.0) 540 (17.1) 528 (21.6) 537 (18.8) 
HPMCAS + 5% PEG 8000 373.5 (5.8) 504 (11.8) 479 (15.0) 450 (12.9) 478 (13.9) 
EDR L + 20% TEC 354.0 (9.0) 486 (14.6) 474 (13.5) 468 (11.6) 476 (13.4) 
EDR RL + 15% TEC 336.9(5.9) 660 (13.1) 660 (11.9) 683 (10.1) 668 (11.8) 
EC + 10% TEC 442.7 (4.8) 629 (6.1) 620 (5.9) 623 (5.8) 624 (5.9) 
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Table 4: TETP from disks based on swellable/erodible polymers  
 
FORMULATION 
TETP 
µm/min (CV) 
HPMC + 5% PEG 400 7.36 (0.33) 
SLP + 10% PEG 400 15.54 (2.28) 
HPC 22.42 (4.17) 
PVA + 5% GLY 37.84 (2.05) 
 
Table(s)
Figure 1: image of a printed disk reporting the 3 concentric circumferences along which thickness 
was measured (outer circumference, white; intermediate circumference, grey; inner circumference, 
black) 
 
Figure 2: test cells before assembly (a) and after filling of the reservoir donor compartment with AAP 
powder (b), positioning of the disk (c) and final assembly (d) 
 
Figure 3: drug recovered vs time profiles obtained from disks based on promptly soluble polymers 
 
Figure 4: individual drug recovered vs time profiles obtained from disks based on HPMC 
 
Figure 5: drug recovered vs time profiles obtained from disks based on insoluble polymers 
 
Figure 6: drug recovered vs time profiles obtained from single (a) and double (b) disks containing 
furosemide; lateral views of disks are also reported 
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